Get all your news in one place.

100's of premium titles.
One app.

Get all your news in one place.

100's of premium titles. One news app.

MYSTERIOUS: Geoff meacham - You Need To See This

Why Citi Is Sounding the Alarm on Moderna Stock

The cancer pipeline gave Moderna's shares a rocket boost. Citi, however, just checked the stock’s price tag and wasn’t exactly impressed.

Barchart · Oct 1

This Analyst Just Downgraded Moderna Stock. Here's Why.

Citi analyst says Moderna stock could crash as much as 60% from here. Here’s why he issued a bearish note on MRNA shares today.

Barchart · Sep 30

Eli Lilly Stock Just Joined the $1 Trillion Club. Should You Buy LLY Here?

Eli Lilly stock inches higher as the company joins the coveted trillion-dollar club. Citi analysts believe LLY shares will push meaningfully higher in 2026.

Barchart · Nov 21, 2025

From analysis to the latest developments in health,
read the most diverse news in one place.

Is It Too Late To Buy Eli Lilly Stock?

Eli Lilly stock has crushed the broader markets in the past 10 years. But should you buy LLY at current levels, given its lofty valuation?

Barchart · Oct 18, 2023

7 Biogen Analysts On Alzheimer's Drug Success As Stock Skyrockets 37%

Shares of Biogen Inc (NASDAQ: BIIB) were flying on Wednesday, after the biopharma company said its experimental Alzheimer’s drug with Japanese partner Eisai showed promising results. RBC Capital Markets On Biogen

Benzinga · Sep 28, 2022

Pfizer, Moderna Analysts Respond To FDA COVID Booster Ruling: 'Revenues Will Decline'

The Food and Drug Administration’s panel of independent vaccine experts recently voted 19 to 2 to recommend a new batch of COVID-19 booster shots targeting the omicron variant this fall. The news, announced Tuesday, June 28, could have a big impact on the share prices of vaccine makers.

Benzinga · Jun 29, 2022

Ahead Of Moderna's Midstage mRNA Flu Vaccine Readout, Analyst Says Drugmaker Likely To Be First To Market

After COVID-19 vaccine-induced strength, Moderna, Inc. (NASDAQ: MRNA) is on the lookout for the next big catalyst to boost its rangebound stock.

Benzinga · Mar 21, 2022

Read news from The Economist, FT, and more,
with one subscription

Coverage From

People

Jim Cramer

550 stories

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

Food and Drug Administration

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.